ScholarIQanswers from OpenAlex & ORCID
Joachim von Pawel
ResearcherPublications, citations & collaboration network
Joachim von Pawel is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Joachim von Pawel have?
ScholarIQindexed works
Joachim von Pawel has 337 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Joachim von Pawel have?
ScholarIQcitation count
Joachim von Pawel has 38,277 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Joachim von Pawel?
ScholarIQh-index
Joachim von Pawel has an h-index of 75 in OpenAlex.
What is the i10-index of Joachim von Pawel?
ScholarIQi10-index
Joachim von Pawel has an i10-index of 180 in OpenAlex.
What is the OpenAlex record for Joachim von Pawel?
ScholarIQopenalex
The OpenAlex for Joachim von Pawel is on the source record.
What are the most-cited papers on Joachim von Pawel?
ScholarIQmost cited works
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer, Fabrice Barlési, Daniel Waterkamp, Keunchil Park, Fortunato Ciardiello, Joachim von Pawel, Shirish M. Gadgeel, Toyoaki Hida, Dariusz M. Kowalski, Manuel Cobo, Diego Cortinovis, Joseph W. Leach, Jonathan Polikoff, Carlos H. Barrios, Fairooz F. Kabbinavar, Osvaldo Arén Frontera, Filippo de Marinis, Hande Turna, Jong-Seok Lee, Marcus Ballinger, Marcin Kowanetz, Pei He, Daniel S. Chen, Alan Sandler, David R. Gandara
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
Giorgio V. Scagliotti, Purvish Parikh, Joachim von Pawel, Bonne Biesma, Johan Vansteenkiste, Christian Manegold, Piotr Serwatowski, U. Gatzemeier, Raghunadharao Digumarti, Mauro Zukin, Jin S. Lee, Anders Mellemgaard, Keunchil Park, Shehkar Patil, Janusz Rolski, Tuncay Göksel, Filippo de Marinis, Lorinda Simms, Katherine P. Sugarman, David R. Gandara
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
Nasser H. Hanna, Frances A. Shepherd, Frank V. Fossella, Jose R. Pereira, Filippo de Marinis, Joachim von Pawel, U. Gatzemeier, Thomas Chang Yao Tsao, Miklos Pless, Thomas Müller, Hong-Liang Lim, Christopher E. Desch, Klára Szondy, Radj Gervais, Shaharyar, Christian Manegold, Sofia Paul, Paolo Paoletti, Lawrence Einhorn, Paul A. Bunn
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
Robert Pirker, Jose R. Pereira, Aleksandra Szczęsna, Joachim von Pawel, Maciej Krzakowski, Rodryg Ramlau, Ihor Vynnychenko, Keunchil Park, Chih-Teng Yu, Valentyn Ganul, Jae-Kyung Roh, Emilio Bajetta, Kenneth J. O’Byrne, Filippo de Marinis, Wilfried Eberhardt, Thomas Goddemeier, Michael Emig, U. Gatzemeier
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial
Martin Reck, R. Kaiser, Anders Mellemgaard, Jean‐Yves Douillard, С. В. Орлов, Maciej Krzakowski, Joachim von Pawel, Maya Gottfried, Igor Bondarenko, Meilin Liao, Claudia-Nanette Gann, José Barrueco, Birgit Gaschler‐Markefski, Silvia Novello